Genentech falls at the last fence in race to market heart drug.
D004345:Drug Industry; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D011994:Recombinant Proteins / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator